Literature DB >> 21915660

[Precursor lesions: epidemiology--is there enough evidence?].

F Hofstädter1.   

Abstract

Exact knowledge of the incidence and prevalence of precursor lesions of malignant diseases would be of great value for the precise evaluation of their potential clinical-pathological progression and therefore for planning and intervention in individual cases and also for planning and evaluation of prevention and early detection strategies. Concerning these high expectations it is surprising that precise data on incidence, prevalence and the exact risk for progression are lacking. Sources of data (cancer registries, specific registries for precursor lesions, early detection programs and specific designed studies) are analyzed concerning their validity and reliability. Imprecise and redundant terminology represents a crucial reason for the lack of data availability.

Entities:  

Mesh:

Year:  2011        PMID: 21915660     DOI: 10.1007/s00292-011-1510-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  8 in total

1.  Prevalence of Barrett's esophagus in the general population: an endoscopic study.

Authors:  Jukka Ronkainen; Pertti Aro; Tom Storskrubb; Sven-Erik Johansson; Tore Lind; Elisabeth Bolling-Sternevald; Michael Vieth; Manfred Stolte; Nicholas J Talley; Lars Agréus
Journal:  Gastroenterology       Date:  2005-12       Impact factor: 22.682

2.  Follow-up findings in young females with high-grade squamous intraepithelial lesion papanicolaou test results.

Authors:  Chengquan Zhao; Pal Kalposi-Novak; R Marshall Austin
Journal:  Arch Pathol Lab Med       Date:  2011-03       Impact factor: 5.534

3.  Estimated long-term effects of the initial 6 years of the German screening colonoscopy program.

Authors:  Hermann Brenner; Lutz Altenhofen; Michael Hoffmeister
Journal:  Gastrointest Endosc       Date:  2010-10       Impact factor: 9.427

4.  Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.

Authors:  Pieter J F de Jonge; Mark van Blankenstein; Caspar W N Looman; Mariël K Casparie; Gerrit A Meijer; Ernst J Kuipers
Journal:  Gut       Date:  2010-08       Impact factor: 23.059

5.  Precancer: a conceptual working definition -- results of a Consensus Conference.

Authors:  Jules J Berman; Jorge Albores-Saavedra; David Bostwick; Ronald Delellis; John Eble; Stanley R Hamilton; Ralph H Hruban; George L Mutter; David Page; Thomas Rohan; William Travis; Donald E Henson
Journal:  Cancer Detect Prev       Date:  2006-10-31

6.  Columnar cell lesions and subsequent breast cancer risk: a nested case-control study.

Authors:  Sarah A Aroner; Laura C Collins; Stuart J Schnitt; James L Connolly; Graham A Colditz; Rulla M Tamimi
Journal:  Breast Cancer Res       Date:  2010-08-06       Impact factor: 6.466

7.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study.

Authors:  Amy C Degnim; Daniel W Visscher; Hal K Berman; Marlene H Frost; Thomas A Sellers; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Piet C de Groen; Wilma L Lingle; Karthik Ghosh; Lois Penheiter; Thea Tlsty; L Joseph Melton; Carol A Reynolds; Lynn C Hartmann
Journal:  J Clin Oncol       Date:  2007-06-11       Impact factor: 44.544

8.  Classifying the precancers: a metadata approach.

Authors:  Jules J Berman; Donald E Henson
Journal:  BMC Med Inform Decis Mak       Date:  2003-06-20       Impact factor: 2.796

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.